FuzzyBot: Importing a new version from external source

2024-03-25T09:03:20Z

Importing a new version from external source

New page

===Cancer===
A study published in 2010 determined that "...meta-analysis of randomised controlled trials suggests that ARBs are associated with a modestly increased risk of new cancer diagnosis. Given the limited data, it is not possible to draw conclusions about the exact risk of cancer associated with each particular drug. These findings warrant further investigation." A later meta-analysis by the U.S. [[Food and Drug Administration]] (FDA) of 31 randomized controlled trials comparing ARBs to other treatment found no evidence of an increased risk of incident (new) cancer, cancer-related death, breast cancer, lung cancer, or prostate cancer in patients receiving ARBs. In 2013, [[comparative effectiveness research]] from the [[United States Department of Veterans Affairs]] on the experience of more than a million [[veterans]] found no increased risks for either [[lung cancer]] or [[prostate cancer]]. The researchers concluded: "In this large nationwide cohort of United States Veterans, we found no evidence to support any concern of increased risk of lung cancer among new users of ARBs compared with nonusers. Our findings were consistent with a protective effect of ARBs."

Translations:Angiotensin II receptor blocker/15/en - Revision history

FuzzyBot: Importing a new version from external source